



Ref: OPL/Share/2020/19
January 28, 2020

Managing Director
Dhaka Stock Exchange Ltd
9/F Motijheel C/A
Dhaka-1000.

Subject : Price Sensitive Information.

Dear Sir,

As per rule no. 33 of the DSE Listing Regulations, 2015, the Board of Directors of Orion Pharma Limited has adopted its un-audited Half-Yearly financial statements in its Board Meeting held on January 28, 2020 at 4:00 pm in the registered office at Orion House, 153-154, Tejgaon I/ A, Dhaka-1208. The following decisions were taken in the meeting :

<u>Particulars</u>	<u>December 31, 2019</u>	<u>December 31, 2018</u>
Consolidated Earnings Per Share (EPS)- Q2	BDT. 2.14	BDT. 2.06
Consolidated NAV per Share - Q2 (Including Revaluation Surplus)	BDT. 75.73	BDT. 73.32
Consolidated NAV per Share - Q2 (Excluding Revaluation Surplus)	BDT. 67.58	BDT. 65.05
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q2	BDT. 3.11	BDT. 4.98

Please acknowledge the receipt.

Thanking you,

Sincerely yours'

Md. Ferdous Jaman
Company Secretary